Amgen stock slips to $330 as year-end pullback hits Wall Street; Fed minutes and MariTide updates in focus
Amgen fell 1% to $329.63 Monday as U.S. stocks closed lower, with tech shares leading declines. Investors are watching for Fed minutes, jobless claims, and updates on Amgen’s obesity drug program. The S&P 500 dropped 0.35%, Nasdaq 0.50%. Amgen expects Phase 2 obesity drug data in late 2025.